Department of Surgery, New York University Grossman School of Medicine and NYC Health and Hospitals-Bellevue, New York, New York.
Department of Surgery, New York University Grossman School of Medicine and NYC Health and Hospitals-Bellevue, New York, New York.
J Surg Res. 2023 Mar;283:1026-1032. doi: 10.1016/j.jss.2022.10.098. Epub 2022 Nov 21.
Tracheostomy in patients with COVID-19 is a controversial and difficult clinical decision. We hypothesized that a recently validated COVID-19 Severity Score (CSS) would be associated with survival in patients considered for tracheostomy.
We reviewed 77 mechanically ventilated COVID-19 patients evaluated for decision for percutaneous dilational tracheostomy (PDT) from March to June 2020 at a public tertiary care center. Decision for PDT was based on clinical judgment of the screening surgeons. The CSS was retrospectively calculated using mean biomarker values from admission to time of PDT consult. Our primary outcome was survival to discharge, and all patient charts were reviewed through August 31, 2021. ROC curve and Youden index were used to estimate an optimal cut-point for survival.
The mean CSS for 42 survivors significantly differed from that of 35 nonsurvivors (CSS 52 versus 66, P = 0.003). The Youden index returned an optimal CSS of 55 (95% confidence interval 43-72), which was associated with a sensitivity of 0.8 and a specificity of 0.6. The median CSS was 40 (interquartile range 27, 49) in the lower CSS (<55) group and 72 (interquartile range 66, 93) in the high CSS (≥55 group). Eighty-seven percent of lower CSS patients underwent PDT, with 74% survival, whereas 61% of high CSS patients underwent PDT, with only 41% surviving. Patients with high CSS had 77% lower odds of survival (odds ratio = 0.2, 95% confidence interval 0.1-0.7).
Higher CSS was associated with decreased survival in patients evaluated for PDT, with a score ≥55 predictive of mortality. The novel CSS may be a useful adjunct in determining which COVID-19 patients will benefit from tracheostomy. Further prospective validation of this tool is warranted.
COVID-19 患者行气管切开术是一个有争议且困难的临床决策。我们假设,最近验证的 COVID-19 严重程度评分(CSS)与接受气管切开术评估的患者的生存率相关。
我们回顾了 2020 年 3 月至 6 月在一家公立三级护理中心接受经皮扩张气管切开术(PDT)决策评估的 77 例机械通气 COVID-19 患者。PDT 的决策基于筛查外科医生的临床判断。CSS 是使用入院至 PDT 咨询时的平均生物标志物值回顾性计算的。我们的主要结局是出院生存率,所有患者的病历均在 2021 年 8 月 31 日前进行了回顾。ROC 曲线和 Youden 指数用于估计生存的最佳切点。
42 例幸存者的平均 CSS 显著低于 35 例非幸存者(CSS 52 与 66,P=0.003)。Youden 指数返回的最佳 CSS 为 55(95%置信区间 43-72),其敏感性为 0.8,特异性为 0.6。较低 CSS(<55)组的中位数 CSS 为 40(四分位距 27,49),较高 CSS(≥55)组为 72(四分位距 66,93)。较低 CSS 组 87%的患者接受了 PDT,生存率为 74%,而较高 CSS 组 61%的患者接受了 PDT,生存率仅为 41%。CSS 较高的患者生存率降低 77%(比值比=0.2,95%置信区间 0.1-0.7)。
较高的 CSS 与接受 PDT 评估的患者生存率降低相关,CSS 评分≥55 预测死亡率。这种新的 CSS 可能是确定 COVID-19 患者是否受益于气管切开术的有用辅助工具。进一步前瞻性验证该工具是必要的。